The cloud-native Torx® platform is the only complete DMTA (design-make-test-analyze) solution on the market. It provides chemistry teams with a centralized location to create, share and manage compounds, synthesis and biological testing. By coordinating activities across internal and external teams it streamlines the drug discovery process, for optimum use of time and budgets whilst ensuring that only mission critical information is shared. Torx enables efficient CRO partner collaboration in the Design, Make and Test stages of the DMTA cycle, offering secure communication vital to project success.
Torx® V2.0 introduces a range of new features which extend the scientific reach and improve the usability of the platform- offering a unique capability for the entire DMTA workflow. Extended molecular docking of newly designed compounds to include covalent ligands, enables medicinal chemists to create 3D pose alongside property predictions to assess their suitability for progression. Furthermore, the new integration with CAS SciFinder enables easy interrogation of synthetic feasibility, reagent availability, and patentability issues.
Join us on June 13 for an informative webinar where Dr. Tim Cheeseright, CEO, Torx Software will discuss the key enhancements, features and benefits offered by the latest release.
If you’re unable to attend, request a demo to see how you can inspire your research teams to work together and deliver faster.
https://www.torx-software.com/about/events/torx-2/
